GTBP - GT Biopharma - Stock Forecast

Healthcare - Sector
Coverage Performance Price Targets & Ratings Chart Insider Trading

GTBP is currently covered by 2 analysts with an average price target of $7.75. This is a potential upside of $4.05 (109.46%) from yesterday's end of day stock price of $3.7.

GT Biopharma's activity chart (see below) currently has 0 price targets and 8 ratings on display. The stock rating distribution of GTBP is 62.5% BUY and 37.5% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 114 days.

Highest price target for GTBP is $5, Lowest price target is $5, average price target is $7.75.

Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 08-Aug-2023. First documented stock forecast 24-Jun-2021.

Best performing analysts who are covering GTBP - GT Biopharma:

Robert Burns Chad Mabry

Currently out of the existing stock ratings of GTBP, 5 are a BUY (62.5%), 3 are a HOLD (37.5%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

5

$0.92 (22.55%)

5

8 months 11 days ago

5/5 (100%)

$-3.63 (-42.06%)

228

Buy

26

$25.74 (9900.00%)

2 years 9 months 26 days ago

0/1 (0%)

$11.72 (82.07%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GTBP (GT Biopharma) average time for price targets to be met?

On average it took 114 days on average for the stock forecasts to be realized with a an average price target met ratio 50

Which analyst has the current highest performing score on GTBP (GT Biopharma) with a proven track record?

ROBERT BURNS

Which analyst has the current lower performing score on GTBP (GT Biopharma) with a proven track record?

CHAD MABRY

Which analyst has the most public recommendations on GTBP (GT Biopharma)?

Robert Burns has 13 price targets and 11 ratings on GTBP

Which analyst is the currently most bullish on GTBP (GT Biopharma)?

Chad Mabry with highest potential upside - $25.74

Which analyst is the currently most reserved on GTBP (GT Biopharma)?

Robert Burns with lowest potential downside - $0.92

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?